GT Biopharma stockholders approve share issuance for May 2025 financings and omnibus plan amendment

GT Biopharma, Inc.

All four director nominees (Breen, Casamento, Kramer, Mun-Gavin) elected with 1.18M+ votes each, no votes under 14K.
Ratification of Weinberg & Company as FY 2025 auditor passed: 1.79M for, 59K against.
Non-binding advisory vote on executive compensation approved: 1.17M for, 20K against.
Approved issuance of up to 19.99% of outstanding common stock related to May 2025 purchase agreements and convertible preferred.
Amendment No. 1 to 2022 Omnibus Incentive Plan, increasing shares by 583,334, approved: 1.15M for, 35K against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.